The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Citi launched its coverage of Structure Therapeutics with a Buy recommendation and a $60 per share target on Friday, citing ...

Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity epidemic, according to Reuters.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

The Italian Medicines Agency is ready to evaluate the reimbursement of new drugs against obesity, following the British model ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Navigating ineffective weight management treatment is a sensitive process that requires acknowledgement of bias from both ...